Post hoc results from the Phase 3 BRIGHTE study report that fostemsavir-based regimens maintained durable virologic suppression and immunologic recovery through Week 240 across baseline HIV-1 viral load subgroups in heavily treatment-experienced adults with multidrug-resistant HIV-1. The analysis indicates sustained effectiveness even among patients starting with different viral load levels, supporting the durability of response for a population where treatment options are often limited. Immunologic endpoints tracked alongside viral suppression. These longer-duration findings can inform treatment selection for clinicians managing multidrug-resistant disease, particularly when durable suppression is the primary goal.